Bing

On the back of these updates, the company stock has come under pressure at the markets. The FDA warnings to Mylan NV (NASDAQ:MYL) are said to be in context of lax production processes being followed at Agila Specialties. This subsidiary was …
wallstreetscope.com · 8/19/2015
In April Teva had offered to pay Mylan shareholders $82 per share in an evenly split cash and stock offer, a 48.3 per cent premium to Mylan’s unaffected stock price on March 10. Mylan quickly rejected Teva’s move. A takeover by Teva would torpedo any ...
Financial Times · 6/1/2015
Mylan's biggest shareholder, Abbott Laboratories, said in June it would vote with Mylan. Mylan made a cash and stock offer now worth about $200 per share in April, saying the Dublin-based generic and over-the-counter drugmaker would be a strategic fit.
Reuters · 8/14/2015
Mylan NV (NASDAQ:MYL) has received a “BBB-” credit standing from Morningstar. The- funding determination firm’s “BBB-” rating means in that the company is a moderate default danger. They additionally …
Las Vegas NV Blog · 9/1/2015
TRENTON, N.J. — Generic drug giant Teva on Tuesday formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring intense scrutiny by antitrust ...
Denver Post · ByLinda A. Johnson · 4/22/2015
At present, 6% of the stock's float is sold short, which would take more than a week to repurchase, at DSX's typical daily trading clip. Looking ahead, the company will hit the earnings confessional on Friday morning. Welcome to Schaeffer's Investment ...
Schaeffer's Investment Research · 7/27/2015
Mylan's takeover had been twice rejected by Perrigo, which had offered it $35.6 billion in cash and stock in April. The decision came just days after Mylan escaped a hostile takeover by Israel-based rival Teva Pharmaceutical Industries Ltd. "Today marks ...
Law 360 · 7/29/2015
Abbott is the largest holder of Mylan after swapping its established-markets drug business for Mylan stock in February. Since then, Mylan shares have surged more than 20 percent as the drugmaker pursues Perrigo Co. and fends off advances from Teva ...
Crain's Chicago Business · 5/8/2015
Should I get rid of Mylan Labs, or hold on? A-You should love this stock. Hold and consider buying more shares of Mylan Laboratories Inc. (around $24 a share, New York Stock Exchange), because it is the class act in the generic drug industry, said Jerry ...
Chicago Tribune · 9/26/1994
Contributing to the strong performance was the sale of Abbott’s branded generic drug business in developed markets to Mylan (NASDAQ:MYL) and its animal health business to Zoetis in February 2015. The company recorded a $1.7 billion gain on the …
Trefis · 7/10/2015

Mylan

Company
Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters …
Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters in Hatfield, Hertfordshire in the United Kingdom. In 2007, Mylan acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, Mylan has grown from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world. Mylan now has approximately 30,000 employees, more than 1,000 separate products, and serves customers in more than 150 countries and territories. Mylan has a global manufacturing output of more than 45 billion doses.
Data from: Wikipedia · Freebase